Amendment: SEC Form S-1/A filed by Cosmos Health Inc.

6/3/25 5:07:47 PM ET

$COSM

Other Pharmaceuticals

Health Care

Get the next $COSM alert in real time by email

Unavailable

Get the next $COSM alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$COSM

Date	Price Target	Rating	Analyst

More analyst ratings

$COSM
Press Releases

Fastest customizable press release news feed in the world

Cosmos Health Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech
CHICAGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today its entry into the U.S. market and the launch of U.S.-based manufacturing through a strategic agreement with DolCas Biotech LLC ("DolCas"), a New Jersey-based developer and manufacturer of clinically studied nutraceutical ingredients. Cosmos Health is set to commence production in the United States at GMP-certified (Good Man
6/24/25 10:55:32 AM ET
$COSM
Other Pharmaceuticals
Health Care
RETRANSMISSION – Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven
CHICAGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights Income Statement Cosmos Health delivered solid results in Q1 2025, highlighted by a significant increase in gross profit and positive performance on both an Adjusted EBITDA and Adjusted Net Income basis, reflecting a
5/15/25 2:30:35 PM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units
CHICAGO, May 07, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has received an additional purchase order for 80,000 units from Pharmalink for its Sky Premium Life products in the United Arab Emirates (UAE). This latest order, pursuant to the exclusive distribution agreement with Pharmalink, follows the successful sell-out of the initial 130,000-unit purchase and supports the Comp
5/7/25 2:30:10 PM ET
$COSM
Other Pharmaceuticals
Health Care

Amendment: SEC Form S-1/A filed by Cosmos Health Inc.

Chat with this insight

Recent Analyst Ratings for
$COSM

$COSM
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Siokas Grigorios bought $15,217 worth of shares (34,004 units at $0.45), increasing direct ownership by 0.56% to 6,158,884 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $62,800 worth of shares (141,825 units at $0.44), increasing direct ownership by 2% to 6,124,880 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $82,000 worth of shares (174,172 units at $0.47), increasing direct ownership by 3% to 5,983,055 units (SEC Form 4)

$COSM
SEC Filings

Amendment: SEC Form S-1/A filed by Cosmos Health Inc.

SEC Form 10-Q filed by Cosmos Health Inc.

Cosmos Health Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

$COSM
Press Releases

Fastest customizable press release news feed in the world

Cosmos Health Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech

RETRANSMISSION – Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven

Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units

$COSM
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Siokas Grigorios bought $15,217 worth of shares (34,004 units at $0.45), increasing direct ownership by 0.56% to 6,158,884 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $62,800 worth of shares (141,825 units at $0.44), increasing direct ownership by 2% to 6,124,880 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $82,000 worth of shares (174,172 units at $0.47), increasing direct ownership by 3% to 5,983,055 units (SEC Form 4)

Amendment: SEC Form S-1/A filed by Cosmos Health Inc.

Chat with this insight

Recent Analyst Ratings for $COSM

$COSM Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Siokas Grigorios bought $15,217 worth of shares (34,004 units at $0.45), increasing direct ownership by 0.56% to 6,158,884 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $62,800 worth of shares (141,825 units at $0.44), increasing direct ownership by 2% to 6,124,880 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $82,000 worth of shares (174,172 units at $0.47), increasing direct ownership by 3% to 5,983,055 units (SEC Form 4)

$COSM SEC Filings

Amendment: SEC Form S-1/A filed by Cosmos Health Inc.

SEC Form 10-Q filed by Cosmos Health Inc.

Cosmos Health Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

$COSM Press Releases

Fastest customizable press release news feed in the world

Cosmos Health Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech

RETRANSMISSION – Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven

Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units

$COSM Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Siokas Grigorios bought $15,217 worth of shares (34,004 units at $0.45), increasing direct ownership by 0.56% to 6,158,884 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $62,800 worth of shares (141,825 units at $0.44), increasing direct ownership by 2% to 6,124,880 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $82,000 worth of shares (174,172 units at $0.47), increasing direct ownership by 3% to 5,983,055 units (SEC Form 4)

Recent Analyst Ratings for
$COSM

$COSM
Insider Trading

$COSM
SEC Filings

$COSM
Press Releases

$COSM
Insider Purchases